NCT06724653Recruiting
Tapering Heart Failure Medication in Patients With Heart Failure With Recovered Ejection Fraction; Open Label Prospective Random Trial
Source: ClinicalTrials.gov · Last updated 27 Mar 2026
Brief summary (registry, in English)
Study start date is on Nov 27th 2024. A patient with an initial ejection fraction (EF) of less than 40%, whose follow-up shows an improvement to an EF of 50% or higher, along with the left ventricular end-diastolic diameter returning to the normal range and taking 3 more heart failure medication randomed to drug tapering group ( RAS blocker or beta blocker) or continuing medication group.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 5 Dec 2024
- Start date
- 6 Mar 2025
- Primary completion date
- 26 May 2025
- Lead sponsor
- Chungnam National University Hospital
- Diseases
- Heart failure
- NCT number
- NCT06724653
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 6 Mar 2025 to the primary completion date, 26 May 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- significant valve disease
- arrhythmia requiring rate control
Age
- under age 18 year
Other
- uncontrolled BP ( over 150/90)
- coronary revascularization within 6 months
- CKD with albuminuria ( over 30mg/g)
- Pregnancy
Who the study is looking for
- initial echocardiogram ejection fraction less than 40%
- follow up echocardiogram ejection fraction over 50% and LVEDD index normal range
- NTprobnp criteria
- eGFR ≥60 ; less 440
- eGFR 45-59: less 980
- eGFR 30-44; less 1220
- eGFR \< 30 : less 5300
- in HD; no criteria for NTproBNP
- on more than 3 heart failure medication ( RAS blocker, beta blocker, mineral corticoid receptor antagonist, SGLT 2 inhibitor)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chungnam National University Hospital Coordinator of this site? Confirm its status | Daejeon | South Korea | Recruiting |
| jeonbuk National University Hospital Coordinator of this site? Confirm its status | Jeonju | South Korea | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.